Uniqure N.v Stock News

CSL Behring and uniQure N.V.''s (NASDAQ: QURE ) Full story available on Benzinga.com

CSL Behring and uniQure N.V.'s (NASDAQ: QURE) etranacogene dezaparvovec, a hemophilia B gene therapy, achieved the pre-specified primary endpoint of non-inferiority in annualized bleeding rate (A

~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a sing

~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec ~

Everence Capital Management Inc. bought a new position in shares of uniQure (NASDAQ:QURE) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 26,770 shares of the biotechnology companys stock, valued at approximately $857,000. Everence Capital Management Inc. owned 0.06% of uniQure []

Capital Asset Advisory Services LLC increased its holdings in shares of uniQure (NASDAQ:QURE) by 4.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,858 shares of the biotechnology companys stock after acquiring an additional 883 shares during the period. Capital []

The objective of Viral Vectors And Plasmid DNA Manufacturing Market report is to define, segment, and project the global industry on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics,

Equities research analysts expect uniQure (NASDAQ:QURE) to report sales of $25.12 million for the current quarter, Zacks reports. Five analysts have made estimates for uniQures earnings, with estimates ranging from $2.00 million to $101.00 million. uniQure reported sales of $34.09 million during the same quarter last year, which would suggest a negative year over year []

The new study on the Global Translational Regenerative Medicine Market 2021-2027 analyzes the crucial capabilities, key infrastructures, major organizations, evaluates measures to attain potential success in the Translational Regenerative Medicine industry. Because of the in-depth overview of the Global Translational

uniQure (NASDAQ:QURE) VP Alexander Edward Kuta III sold 6,000 shares of the firms stock in a transaction that occurred on Monday, November 15th. The stock was sold at an average price of $31.81, for a total transaction of $190,860.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []

uniQure (NASDAQ:QURE) VP Alexander Edward Kuta III sold 6,000 shares of the stock in a transaction on Monday, November 15th. The shares were sold at an average price of $31.81, for a total value of $190,860.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC []

Cubist Systematic Strategies LLC lifted its position in shares of uniQure (NASDAQ:QURE) by 101.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,193 shares of the biotechnology companys stock after acquiring an additional 13,693 shares during the quarter. Cubist []

QURE is a leader in gene therapy, and has the first commercially licensed gene therapy manufacturing facility. Utilizing their industry leading technology, they are developing treatments and cures for

The recent rise can be attributed to its Q3 loss of $0.79 per share, which was better than the consensus estimate of $1.05 loss per share.

Oral Presentation to Highlight AMT-191 for Fabry Disease Oral Presentation to Highlight AMT-191 for Fabry Disease